Latest COPD Stories
- Divestiture permits Actavis to enhance focus on core strategic therapeutic categories - DUBLIN, Feb.
-- In Quebec alone 386,000 people suffer from COPD and it is the fourth leading cause of death in Canada.
Phase 3 registrational studies of TD-4208 are anticipated to begin in 2015 GEORGE TOWN, Grand Cayman and PITTSBURGH, Feb. 2, 2015 /PRNewswire/ -- Theravance Biopharma, Inc.
New choice between mist and dry powder inhalers for tiotropium RIDGEFIELD, Conn., Jan. 21, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
Studies show success across multiple chronic conditions and demographics NORWALK, Conn., Jan.
HEIDELBERG, Germany, January 5, 2015 /PRNewswire/ -- BioMed X announced today that they have entered into a collaboration agreement with Boehringer Ingelheim to establish
DUBLIN , Dec.
Study shows greatest cost linked to people with depression, COPD, coronary artery disease and dementia ABBOTT PARK, Ill., Dec.
LONDON, December 3, 2014 /PRNewswire/ -- Opportunities for Leading Companies Report Details Asthma and COPD therapies - new study showing you